 In summary, if 9 patients are treated at a certain dose and at least 7 out of 9 individuals respond to treatment per serum glutamine levels and 3 develop DLT, this dose level will be declared the Recommended Phase 2 Dose RP2D. Six additional patients total of 15 to 18 patients will be enrolled at the RP2D level to better assess toxicity and to document responses. 